Raza Faisal, Zafar Hajra, Zhang Shulei, Kamal Zul, Su Jing, Yuan Wei-En, Mingfeng Qiu
School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal Dir (Upper), Khyber Pakhtunkhwa, 18000, Pakistan.
Adv Healthc Mater. 2021 Mar;10(6):e2002081. doi: 10.1002/adhm.202002081. Epub 2021 Feb 15.
Immunotherapy will significantly impact the standard of care in cancer treatment. Recent advances in nanotechnology can improve the efficacy of cancer immunotherapy. However, concerns regarding efficiency of cancer nanomedicine, complex tumor microenvironment, patient heterogeneity, and systemic immunotoxicity drive interest in more novel approaches to be developed. For this purpose, biomimetic nanoparticles are developed to make innovative changes in the delivery and biodistribution of immunotherapeutics. Biomimetic nanoparticles have several advantages that can advance the clinical efficacy of cancer immunotherapy. Thus there is a greater push toward the utilization of biomimetic nanotechnology for developing effective cancer immunotherapeutics that demonstrate increased specificity and potency. The recent works and state-of-the-art strategies for anti-tumor immunotherapeutics are highlighted here, and particular emphasis has been given to the applications of cell-derived biomimetic nanotechnology for cancer immunotherapy.
免疫疗法将显著影响癌症治疗的护理标准。纳米技术的最新进展可以提高癌症免疫疗法的疗效。然而，对癌症纳米药物的效率、复杂的肿瘤微环境、患者异质性以及全身免疫毒性的担忧促使人们对开发更新颖的方法产生兴趣。为此，人们开发了仿生纳米颗粒，以便在免疫疗法的递送和生物分布方面做出创新性改变。仿生纳米颗粒具有若干优势，可提高癌症免疫疗法的临床疗效。因此，人们更倾向于利用仿生纳米技术来开发有效的癌症免疫疗法，这些疗法具有更高的特异性和效力。本文重点介绍了抗肿瘤免疫疗法的最新研究成果和前沿策略，尤其强调了细胞衍生的仿生纳米技术在癌症免疫疗法中的应用。
